Pertinax Pharma launches patented chlorhexidine technology
Novel materials enable controlled and sustained release of chlorhexidine
Pertinax Pharma today announces the commercial launch of its unique, proprietary Pertinax® technology, which provides controlled and sustained delivery of chlorhexidine (CHX). The revolutionary new technology has a wide range of potential applications across the wound care, dentistry, medical device and veterinary markets. The advantage of Pertinax is that, unlike conventional CHX products, it does not dissipate rapidly and can provide precisely measured antimicrobial efficacy over days, weeks, months or even years. Consequently, Pertinax has the potential to significantly improve a wide range of existing CHX products, whilst also opening up a number of entirely new applications.
Polyurethane Pertinax woundcare foam
Pertinax Pharma
Pertinax was originally developed at the University of Bristol with primarily dental and oral hygiene applications in mind but over the past 2 years the company has validated the material in a very broad range of clinical and veterinary applications. A UK patent for the technology was granted in November 2015, and a US patent was granted in August of this year. To date, eight peer reviewed papers* have been published on the use of Pertinax in a variety of applications, demonstrating the technology’s broad applicability, efficacy and safety.
Pertinax offers two key advantages over conventional CHX formulations. The material requires lower quantities of CHX, with continuous antimicrobial function provided by less frequent applications than conventional CHX products. The material also exhibits lower cytotoxicity than equivalent concentrations of conventional CHX.
Ashley Cooper, CEO at Pertinax Pharma, commented: “Since the inception of the company, we have focussed our efforts and investment on the characterisation of Pertinax materials and the development of a scalable manufacturing process. Having achieved these major milestones, we are now ready and eager to engage with prospective commercial partners”.
Dr. Michele Barbour, CSO, remarked: “Our unique, patented technology has wide potential application across human and vetinerary medicine. While there is scope for application across multiple sectors, wound care is our initial focus. Our technology is especially well suited to this field including in polyurethanes, alginates, acrylics and silicones”.
The company is actively seeking commercial partners in the wound care and medical device industries. Pertinax is available in kilogram quantities for development purposes, and the company plans to establish commercial cGMP production over the next 12 to 18 months.
Pertinax materials will be regulated under the EU Medicines Directive as a new active pharmaceutical ingredient (API) or under the EU Biocide Regulations as a biocide depending on the intended use – with the reduction of antiseptic usage an appealing plus point for regulators.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
